May 16th 2025
A pediatric patient with a rare genetic disorder safely received a personalized CRISPR therapy, marking the first known case of a personalized CRISPR-based medicine administered to a single patient.
CHMP Grants Positive Opinion for Pfizer/Merck KGaA Cancer Drug Plus Axitinib for Kidney Cancer
September 23rd 2019The Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a positive opinion recommending marketing authorization for Bavencio (avelumab) in combination with axitinib for treating kidney cancer.
Preparing for a Growing Biologics Market
August 15th 2019BioPharm International spoke with Cindy Reiss-Clark, vice president, general manager, Biologics at West Pharmaceutical Services Inc., about the growing biologics market, specifically gene therapies, and how West is helping their clients prepare for these new trends.
Improvement in CAR T-Cell Therapy Removes Severe Side Effects
April 24th 2019University of Southern California scientists have made an advancement in chimeric antigen receptor (CAR) T-cell therapy that seems to eliminate its severe side effects, making the treatment safer and potentially available in outpatient settings.